ArticleAlzheimer's research & therapy2020
Clinical significance of focal ß-amyloid deposition measured by
Article in Alzheimer's research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Amyloid-β PET Radioligands in Alzheimer's Disease: From Plaque Detection to Biomarker-Guided Patient Stratification and Therapeutic Monitoring.Molecular diagnosis & therapy · 2026Review
- Centiloid values from deep learning-based CT parcellation: a valid alternative to freesurfer.Alzheimer's research & therapy · 2025Article
- Beyond binary classification: Comparing three region-based multi-phase Aβ staging systems.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Establishing Regional Aβ Cutoffs and Exploring Subgroup Prevalence Across Cognitive Stages Using BeauBrain AmyloDementia and neurocognitive disorders · 2025Article
- Feasibility and safety of cortical access point biopsy during hydrocephalus shunt surgery.Brain & spine · 2025Article
- Association between focal amyloid deposition and cognitive impairment in individuals below the amyloid threshold.Frontiers in aging neuroscience · 2024Article
- Quantitative comparative analysis of amyloid PET images using three radiopharmaceuticals.Annals of nuclear medicine · 2023Article
- Clinical outcomes of increased focal amyloid uptake in individuals with subthreshold global amyloid levels.Frontiers in aging neuroscience · 2023Article
- Development and clinical validation of CT-based regional modified Centiloid method for amyloid PET.Alzheimer's research & therapy · 2022Article
- The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment.Alzheimer's research & therapy · 2022Article
- Patterns of Focal Amyloid Deposition UsingDiagnostics (Basel, Switzerland) · 2022Article
- Amyloid-PET Levels in the Precuneus and Posterior Cingulate Cortices Are Associated with Executive Function Scores in Preclinical Alzheimer's Disease Prior to Overt Global Amyloid Positivity.Journal of Alzheimer's disease : JAD · 2022Article
- Cognitive trajectories of patients with focal ß-amyloid deposition.Alzheimer's research & therapy · 2021Article
- Association of PET-based stages of amyloid deposition with neuropathological markers of Aβ pathology.Annals of clinical and translational neurology · 2021Article
- Association Between Amyloid Accumulation and Sleep in Patients With Idiopathic REM Sleep Behavior Disorder.Frontiers in neurology · 2020Article
- Involvement of specific striatal subregion contributes to executive deficits in Alzheimer disease.Journal of psychiatry & neuroscience : JPNArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 14 institutions in 1 country.
Funding
Abstract
backgroundAlthough amyloid PET of typical Alzheimer's disease (AD) shows diffuse ß-amyloid (Aß) deposition, some patients show focal deposition. The clinical significance of this focal Aß is not well understood. We examined the clinical significance of focal Aß deposition in terms of cognition as well as Aß and tau cerebrospinal fluid (CSF) levels. We further evaluated the order of Aß accumulation by visual assessment.
methodsWe included 310 subjects (125 cognitively unimpaired, 125 mild cognitive impairment, and 60 AD dementia) from 9 referral centers. All patients underwent neuropsychological tests and
results53/310 (17.1%) subjects were classified as Focal-FMM. The cognitive level of the Focal-FMM group was better than that of Diffuse-FMM group and worse than that of No-FMM group. Among the Focal-FMM group, those who had FMM uptake to a larger extent or in the striatum had worse cognitive levels. Compared to the Diffuse-FMM group, the Focal-FMM group had a less AD-like CSF profile (increased Aß42 and decreased t-tau, t-tau/Aß42). Among the Focal-FMM group, Aß deposition was most frequently observed in the frontal (62.3%) and least frequently observed in the striatum (43.4%) and temporal (39.6%) regions.
conclusionsWe suggest that focal Aß deposition is an intermediate stage between no Aß and diffuse Aß deposition. Furthermore, among patients with focal Aß deposition, those who have Aß to a larger extent and striatal involvement show clinical features close to diffuse Aß deposition. Further longitudinal studies are needed to evaluate the disease progression of patients with focal Aß deposition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.